Persistent immune activation and carotid atherosclerosis in HIV-infected ugandans receiving antiretroviral therapy

Journal of Infectious Diseases

Volumn 213, Issue 3, 2016, Pages 370-378

  Siedner, Mark J ^a,b   Kim, June Ho ^a,b   Nakku, Ruth Sentongo ^f   Bibangambah, Prossy ^f   Hemphill, Linda ^a,b   Triant, Virginia A ^a,b   Haberer, Jessica E ^a,b   Martin, Jeffrey N ^d   Mocello, A Rain ^d   Boum, Yap ^g   Kwon, Douglas S ^a   Tracy, Russell P ^e   Burdo, Tricia ^c   Huang, Yong ^d   Cao, Huyen ^d   Okello, Samson ^f   Bangsberg, David R ^a,b,f   Hunt, Peter W ^d  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c BOSTON COLLEGE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF VERMONT   (United States)

^f MBARARA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Uganda)

^g EPICENTRE   (France)

Author keywords

aging; antiretroviral therapy; atherosclerosis; carotid intima media thickness; HIV AIDS; inflammation; Uganda

Indexed keywords

ANTIRETROVIRUS AGENT; CD14 ANTIGEN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BIOLOGICAL MARKER; CYTOKINE; LEUKOCYTE ANTIGEN;

ADULT; AGE; ARTERIAL WALL THICKNESS; ARTICLE; CARDIOVASCULAR RISK; CAROTID ATHEROSCLEROSIS; CD4 LYMPHOCYTE COUNT; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ECHOGRAPHY; FEMALE; HEMOGLOBIN BLOOD LEVEL; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOREACTIVITY; LIPID ANALYSIS; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OBESITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; SMOKING; UGANDAN; VIRUS LOAD; BLOOD; CAROTID ARTERY DISEASES; COMPLICATION; GENE EXPRESSION REGULATION; GENETICS; HIV INFECTIONS; IMMUNOLOGY; METABOLISM; RISK FACTOR; UGANDA;

ANTI-HIV AGENTS; ANTIGENS, CD; BIOMARKERS; CAROTID ARTERY DISEASES; COHORT STUDIES; CYTOKINES; FEMALE; GENE EXPRESSION REGULATION; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; UGANDA;

EID: 84960375102     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiv450     Document Type: Article

References (50)

1. Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 2008; 372: 293-9.
2. Lima VD, Hogg RS, Harrigan PR,. et al. Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy. AIDS 2007; 21: 685-92.
3. Friis-Moller N, Reiss P, Sabin CA,. et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007; 356: 1723-35.
4. Chow FC, Regan S, Feske S, Meigs JB, Grinspoon SK, Triant VA. Comparison of ischemic stroke incidence in HIV-infected and non-HIV-infected patients in a US health care system. J Acquir Immune Defic Syndr 2012; 60: 351-8.
5. Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab 2007; 92: 2506-12.
6. Marcus JL, Leyden WA, Chao CR,. et al. HIV infection and incidence of ischemic stroke. AIDS 2014; 28: 1911-9.
7. Freiberg MS, Chang CC, Kuller LH,. et al. HIV infection and the risk of acute myocardial infarction. JAMA Intern Med 2013; 173: 614-22.
8. El-Sadr WM, Lundgren JD, Neaton JD,. et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355: 2283-96.
9. Brenchley JM, Price DA, Schacker TW,. et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006; 12: 1365-71.
10. Hunt PW, Brenchley J, Sinclair E,. et al. Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J Infect Dis 2008; 197: 126-33.
11. Subramanian S, Tawakol A, Burdo TH,. et al. Arterial inflammation in patients with HIV. JAMA 2012; 308: 379-86.
12. Duprez DA, Neuhaus J, Kuller LH,. et al. Inflammation, coagulation and cardiovascular disease in HIV-infected individuals. PLoS One 2012; 7: e44454.
13. McKibben RA, Margolick JB, Grinspoon S,. et al. Elevated levels of monocyte activation markers are associated with subclinical atherosclerosis in men with and those without HIV infection. J Infect Dis 2015; 211: 1219-28.
14. Ross AC, Rizk N, O'Riordan MA,. et al. Relationship between inflammatory markers, endothelial activation markers, and carotid intima-media thickness in HIVinfected patients receiving antiretroviral therapy. Clin Infect Dis 2009; 49: 1119-27.
15. Triant VA, Grinspoon SK. Immune dysregulation and vascular risk in HIV-infected patients: implications for clinical care. J Infect Dis 2011; 203: 439-41.
16. Triant VA, Meigs JB, Grinspoon SK. Association of C-reactive protein and HIV infection with acute myocardial infarction. J Acquir Immune Defic Syndr 2009; 51: 268-73.
17. UNAIDS Report on the Global AIDS Epidemic. UNAIDS. 2013. http: //www. unaids.org/sites/default/files/en/media/unaids/contentassets/documents/epide miology/2013/gr2013/UNAIDS-Global-Report-2013-en.pdf. Accessed 1 March 2015.
18. Chambless LE, Heiss G, Folsom AR,. et al. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC) Study, 1987-1993. AmJ Epidemiol 1997; 146: 483-94.
19. Hodis HN, Mack WJ, LaBree L,. et al. The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann Intern Med 1998; 128: 262-9.
20. Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-Analysis. Circulation 2007; 115: 459-67.
21. O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK Jr. Carotid-Artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med 1999; 340: 14-22.
22. Hunt PW, Cao HL, Muzoora C,. et al. Impact of CD8+ T-cell activation on CD4+ T-cell recovery and mortality in HIV-infected Ugandans initiating antiretroviral therapy. AIDS 2011; 25: 2123-31.
23. Siedner MJ, Lankowski A, Tsai AC,. et al. GPS-measured distance to clinic, but not self-reported transportation factors, are associated with missed HIV clinic visits in rural Uganda. AIDS 2013; 27: 1503-8.
24. Byakwaga H, Boum Y II, Huang Y,. et al. The kynurenine pathway of tryptophan catabolism, CD4+ T-cell recovery, and mortality among HIV-infected Ugandans initiating antiretroviral therapy. J Infect Dis 2014; 210: 383-91.
25. Stein JH, Korcarz CE, Hurst RT,. et al. Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force. Endorsed by the Society for Vascular Medicine. J Am Soc Echocardiogr 2008; 21: 93-111; quiz 89-90.
26. Korcarz CE, Hirsch AT, Bruce C,. et al. Carotid intima-media thickness testing by non-sonographer clinicians: the office practice assessment of carotid atherosclerosis study. J Am Soc Echocardiogr 2008; 21: 117-22.
27. Touboul PJ, Hernandez-Hernandez R, Kucukoglu S,. et al. Carotid artery intima media thickness, plaque and Framingham cardiovascular score in Asia, Africa/ Middle East and Latin America: the PARC-AALA study. Int J Cardiovasc Imaging 2007; 23: 557-67.
28. Bendavid E, Ford N, Mills EJ. HIV and Africa's elderly: the problems and possibilities. AIDS 2012; 26(suppl 1): S85-91.
29. Mills EJ, Barnighausen T, Negin J. HIV and aging-preparing for the challenges ahead. N Engl J Med 2012; 366: 1270-3.
30. Negin J, Barnighausen T, Lundgren JD, Mills EJ. Aging with HIV in Africa: the challenges of living longer. AIDS 2012; 26(suppl 1): S1-5.
31. Hsue PY, Deeks SG, Hunt PW. Immunologic basis of cardiovascular disease in HIV-infected adults. J Infect Dis 2012; 205(suppl 3): S375-82.
32. Sandler NG, Wand H, Roque A,. et al. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis 2011; 203: 780-90.
33. Mendez-Lagares G, Romero-Sanchez MC, Ruiz-Mateos E,. et al. Long-term suppressive combined antiretroviral treatment does not normalize the serum level of soluble CD14. J Infect Dis 2013; 207: 1221-5.
34. Reiner AP, Lange EM, Jenny NS,. et al. Soluble CD14: genomewide association analysis and relationship to cardiovascular risk and mortality in older adults. Arterioscler Thromb Vasc Biol 2013; 33: 158-64.
35. Longenecker CT, Jiang Y, Orringer CE,. et al. Soluble CD14 is independently associated with coronary calcification and extent of subclinical vascular disease in treated HIV infection. AIDS 2014; 28: 969-77.
36. Hsue PY, Scherzer R, Hunt PW,. et al. Carotid intima-media thickness progression in HIV-infected adults occurs preferentially at the carotid bifurcation and is predicted by inflammation. J Am Heart Assoc 2012; 1: 1-12.
37. Kelesidis T, Kendall MA, Yang OO, Hodis HN, Currier JS. Biomarkers of microbial translocation and macrophage activation: association with progression of subclinical atherosclerosis in HIV-1 infection. J Infect Dis 2012; 206: 1558-67.
38. Favre D, Mold J, Hunt PW,. et al. Tryptophan catabolism by indoleamine 2, 3-dioxygenase 1 alters the balance of TH17 to regulatory T cells in HIV disease. Sci Transl Med 2010; 2: 32ra6.
39. Vujkovic-Cvijin I, Dunham RM, Iwai S,. et al. Dysbiosis of the gut microbiota is associated with HIV disease progression and tryptophan catabolism. Sci Transl Med 2013; 5: 193ra91.
40. Niinisalo P, Raitala A, Pertovaara M,. et al. Indoleamine 2, 3-dioxygenase activity associates with cardiovascular risk factors: the Health 2000 study. Scand J Clin Lab Invest 2008; 68: 767-70.
41. Wirleitner B, Rudzite V, Neurauter G,. et al. Immune activation and degradation of tryptophan in coronary heart disease. Eur J Clin Invest 2003; 33: 550-4.
42. Kato A, Suzuki Y, Suda T,. et al. Relationship between an increased serum kynurenine/ tryptophan ratio and atherosclerotic parameters in hemodialysis patients. Hemodial Int 2010; 14: 418-24.
43. Kuller LH, Tracy R, Belloso W,. et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008; 5: e203.
44. Merlini E, Luzi K, Suardi E,. et al. T-cell phenotypes, apoptosis and inflammation in HIV+ patients on virologically effective cART with early atherosclerosis. PLoS One 2012; 7: e46073.
45. Burdo TH, Lentz MR, Autissier P,. et al. Soluble CD163 made by monocyte/macrophages is a novel marker of HIV activity in early and chronic infection prior to and after anti-retroviral therapy. J Infect Dis 2011; 204: 154-63.
46. Burdo TH, Lo J, Abbara S,. et al. Soluble CD163, a novel marker of activated macrophages, is elevated and associated with noncalcfied coronary plaque in HIV-infected patients. J Infect Dis 2011; 204: 1227-36.
47. Moreno JA, Munoz-Garcia B, Martin-Ventura JL,. et al. The CD163-expressing macrophages recognize and internalize TWEAK: potential consequences in atherosclerosis. Atherosclerosis 2009; 207: 103-10.
48. Longenecker CT, Funderburg NT, Jiang Y,. et al. Markers of inflammation and CD8 T-cell activation, but not monocyte activation, are associated with subclinical carotid artery disease in HIV-infected individuals. HIV Med 2013; 14: 385-90.
49. Volpe GE, Tang AM, Polak JF, Mangili A, Skinner SC, Wanke CA. Progression of carotid intima-media thickness and coronary artery calcium over 6 years in an HIV-infected cohort. J Acquir Immune Defic Syndr 2013; 64: 51-7.
50. Klein DB, LeydenWA, Xu L,. et al. Declining relative risk for myocardial infarction among HIV-positive compared with HIV-negative individuals with access to care. Clin Infect Dis 2015; 60: 1278-80.